Company invites individual and institutional investors and advisors to attend

BOTHELL, Wash and VANCOUVER, British Columbia, Oct. 30, 2017 – Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisine for smoking cessation, today announced that Rick Stewart, Chairman and Chief Executive Officer, will be presenting live at on November 2, 2017.

Achieve will be providing a brief history of the company, an update on cytisine and its clinical development program, including current phase 1 studies and near-term Phase 3 plans. Investors will have the opportunity to ask questions in real-time, as this is a live, interactive online event. Questions may be asked both in the presentation hall and in the association’s “virtual trade booth.” Should attendees not be able to join on the day, an on-demand archive will be made available for 90 days after the webcast.

“We are extremely pleased to have been invited to present at this live, interactive event. It is an excellent opportunity for us to provide an update on our company and clinical development plans for cytisine,” said Rick Stewart.

Achieve will present on Thursday, November 2, 2017 at 1:00 pm ET at It is recommended that attendees pre-register to receive event updates in advance:


About Achieve and Cytisine
Achieve is developing cytisine as a smoking cessation aid. Cytisine is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe for more than 20 years. It is estimated that over 20 million people have used cytisine to help combat nicotine addiction, including approximately 2,000 patients in Phase 3 clinical trials conducted in Europe and New Zealand. Achieve’s focus is to address the global smoking health epidemic, which is currently the leading cause of preventable death and is responsible for nearly six million people losing their lives annually worldwide. Discussions have been held with the FDA and European regulatory agencies to determine the clinical and regulatory pathway towards making cytisine widely available.


About VirtualInvestorConferen